UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2478) 2478
Newspaper Article (211) 211
Newsletter (87) 87
Magazine Article (18) 18
Dissertation (12) 12
Book Chapter (10) 10
Publication (3) 3
Transcript (3) 3
Conference Proceeding (2) 2
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
lopinavir (2225) 2225
humans (1735) 1735
science & technology (1691) 1691
life sciences & biomedicine (1577) 1577
hiv infections - drug therapy (1225) 1225
male (956) 956
female (935) 935
infectious diseases (865) 865
adult (812) 812
ritonavir (740) 740
ritonavir - therapeutic use (687) 687
hiv (624) 624
pharmacology & pharmacy (586) 586
pyrimidinones - therapeutic use (535) 535
hiv protease inhibitors - therapeutic use (528) 528
middle aged (516) 516
human immunodeficiency virus--hiv (500) 500
immunology (467) 467
anti-hiv agents - therapeutic use (463) 463
ritonavir - administration & dosage (463) 463
drug therapy (410) 410
drug therapy, combination (403) 403
antiretroviral drugs (402) 402
protease inhibitors (398) 398
hiv infections - virology (393) 393
virology (390) 390
antiviral agents (384) 384
aids/hiv (375) 375
pyrimidinones - administration & dosage (357) 357
viral load (344) 344
lopinavir - therapeutic use (341) 341
treatment outcome (335) 335
ritonavir - adverse effects (330) 330
hiv-1 - drug effects (322) 322
coronaviruses (316) 316
hiv protease inhibitors - administration & dosage (314) 314
drug combinations (310) 310
microbiology (299) 299
anti-hiv agents - administration & dosage (288) 288
covid-19 (286) 286
antiretroviral therapy (272) 272
pyrimidinones - adverse effects (267) 267
hiv protease inhibitors - adverse effects (265) 265
health aspects (256) 256
cd4 lymphocyte count (245) 245
research (236) 236
hiv infection (235) 235
highly active antiretroviral therapy (224) 224
ritonavir - pharmacokinetics (217) 217
antiretroviral therapy, highly active (216) 216
drugs (213) 213
lopinavir - administration & dosage (212) 212
clinical trials (210) 210
hiv protease inhibitors - pharmacology (208) 208
lopinavir/ritonavir (208) 208
virus diseases (208) 208
pyrimidinones - pharmacokinetics (207) 207
anti-hiv agents - adverse effects (204) 204
hiv-1 (198) 198
hiv protease inhibitors - pharmacokinetics (196) 196
adolescent (188) 188
drug interactions (188) 188
tenofovir (185) 185
patients (181) 181
hiv-1 - genetics (174) 174
ritonavir - pharmacology (174) 174
pharmacokinetics (172) 172
analysis (168) 168
young adult (168) 168
proteases (167) 167
pyrimidinones - pharmacology (167) 167
efavirenz (166) 166
human immunodeficiency virus (166) 166
atazanavir sulfate (156) 156
drug administration schedule (156) 156
animals (155) 155
mutation (153) 153
dosage and administration (151) 151
anti-hiv agents - pharmacokinetics (147) 147
pharmacology (145) 145
reverse transcriptase inhibitors - therapeutic use (145) 145
hiv infections - blood (143) 143
aids (141) 141
proteinase inhibitors (140) 140
medical research (139) 139
care and treatment (138) 138
child (138) 138
rna, viral - blood (137) 137
drug resistance (136) 136
risk factors (135) 135
hiv infections - complications (133) 133
darunavir (132) 132
prospective studies (132) 132
antiretroviral agents (131) 131
acquired immune deficiency syndrome--aids (130) 130
aged (130) 130
anti-hiv agents (130) 130
lopinavir - adverse effects (128) 128
infant (125) 125
pregnancy (122) 122
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2694) 2694
Spanish (71) 71
German (28) 28
French (21) 21
Portuguese (17) 17
Chinese (10) 10
Japanese (9) 9
Russian (9) 9
Italian (3) 3
Afrikaans (1) 1
Czech (1) 1
Dutch (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 03/2020, Volume 382, Issue 19, pp. 1787 - 1799
Investigators in China report the results of an open-label, randomized clinical trial of lopinavir–ritonavir for the treatment of Covid-19 in 199 infected... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Pandemics | Clinical Laboratory Techniques | Coronavirus Infections - drug therapy | Humans | Middle Aged | Pneumonia, Viral - drug therapy | Male | Coronavirus Infections - mortality | Viral Load | Ritonavir - adverse effects | Treatment Failure | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Betacoronavirus - isolation & purification | Hospital Mortality | Time-to-Treatment | Antiviral Agents - therapeutic use | Coronavirus Infections - diagnosis | Proportional Hazards Models | Reverse Transcriptase Polymerase Chain Reaction | Patient Acuity | Coronavirus Infections - virology | Antiviral Agents - adverse effects | Intention to Treat Analysis | Lopinavir - therapeutic use | Aged | Pneumonia, Viral - mortality | Cytochrome P-450 CYP3A Inhibitors - adverse effects | Cytochrome P-450 CYP3A Inhibitors - therapeutic use | Betacoronavirus - genetics | Pneumonia, Viral - virology | Lopinavir - adverse effects | Drug therapy, Combination | Ritonavir | Lopinavir | Testing | Pneumonia | Oxygen | Laboratories | Clinical trials | Coronaviruses | Ribonucleic acid--RNA | Patients | Middle East respiratory syndrome | Clinical outcomes | Severe acute respiratory syndrome coronavirus 2 | COVID-19 | Human immunodeficiency virus--HIV | Influenza | Respiratory diseases | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Journal Article
Journal of neurovirology, ISSN 1538-2443, 09/2015, Volume 22, Issue 2, pp. 170 - 178
Journal Article
Nature communications, ISSN 2041-1723, 01/2020, Volume 11, Issue 1, pp. 222 - 222
Journal Article
PloS one, ISSN 1932-6203, 2015, Volume 10, Issue 12, pp. e0145772 - e0145772
The increasing prevalence of acquired and transmitted HIV-1 drug resistance is an obstacle to successful antiretroviral therapy (ART) in the low- and... 
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Lopinavir - pharmacology | HIV-1 - drug effects | Humans | Reverse Transcriptase Inhibitors - pharmacology | HIV-1 - genetics | Mutation - genetics | Atazanavir Sulfate - therapeutic use | Protease Inhibitors - pharmacology | Drug Resistance, Viral - genetics | Darunavir - pharmacology | Point-of-Care Systems | Treatment Failure | Ritonavir - therapeutic use | Atazanavir Sulfate - pharmacology | HIV Infections - drug therapy | Lopinavir - therapeutic use | Ritonavir - pharmacology | Reverse Transcriptase Inhibitors - therapeutic use | Drug Therapy, Combination | Genotyping Techniques - methods | Protease Inhibitors - therapeutic use | Darunavir - therapeutic use | Antiviral agents | Care and treatment | Control | Disease transmission | Genotype | Dosage and administration | Research | HIV infection | Risk factors | Antiretroviral drugs | RNA-directed DNA polymerase | Pandemics | Laboratories | Viruses | Drug resistance | Medical screening | Antiretroviral therapy | Load tests | Disease prevention | Protease inhibitors | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Human immunodeficiency virus--HIV | Point mutation | Levels | Mutation | Index Medicus | AIDS | HIV | Acquired immune deficiency syndrome | Human immunodeficiency virus
Journal Article